Trial Profile
An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento in Subjects with Von Willebrand Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Factor VIII/von Willebrand factor (Primary)
- Indications Von Willebrand disease
- Focus Therapeutic Use
- Sponsors CSL Behring
- 21 Feb 2018 Status changed from recruiting to completed.
- 19 Aug 2017 Planned End Date changed from 1 Feb 2018 to 15 Feb 2018.
- 16 Aug 2017 Planned primary completion date changed from 1 Feb 2018 to 15 Feb 2018.